Xenon Pharmaceuticals Inc
XENE
Market Cap$3.04B
Close$
$2.06
94.8% downside
Current Fair Value
94.8% downsideOvervalued by 94.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.04 Billion |
|---|---|
| Enterprise Value | $2.52 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.5 |
| Beta | 0.64 |
| Outstanding Shares | 75,468,883 |
| Avg 30 Day Volume | 336,320 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -18.56 |
|---|---|
| PEG | -35.47 |
| Price to Sales | - |
| Price to Book Ratio | 4.98 |
| Enterprise Value to Revenue | 19063.04 |
| Enterprise Value to EBIT | -13.52 |
| Enterprise Value to Net Income | -16 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
ESG Score
No data
About Xenon Pharmaceuticals Inc
CEO: Simon Pimstone